US Stock Market Movement: United Therapeutics Surges on October 1 Due to Patent Victory, Rating Upgrade, and Pulmonary Hypertension Drug
Bitget异动解读2026/10/01 13:55United Therapeutics October 1st Major Surge Explained
Keywords: patent victory, rating upgrade, pulmonary hypertension drug
1. On September 30, 2026, the United States District Court for the District of Delaware ruled that Liquidia infringed claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327, which relate to inhaled treprostinil for the treatment of pulmonary arterial hypertension associated with interstitial lung disease. United Therapeutics plans to seek the withdrawal of approval for Yutrepia in related indications and seek damages for infringement.
2. On October 1, 2026, BTIG upgraded United Therapeutics’ rating from "Neutral" to "Buy," setting a target price of $728. United Therapeutics currently sells pulmonary arterial hypertension treatments such as inhaled Tyvaso and Tyvaso DPI. The court ruling limits Liquidia’s competitive path for Yutrepia.
(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eni Group and Repsol plan to transfer partial ownership of Venezuelan gas fields
Besennt states Iranian offshore oil in transit will drop to zero this week
Renault Group will invest over 10 billion euros in France in the coming years to develop electric vehicles.
The CEO of Renault Group stated that the group will invest more than 10 billion euros in France over the next few years to develop electric vehicles and affordable models. Thanks to the growth in electric vehicle production, Renault Group expects its domestic output in France to increase by more than 25% by 2026.
Crypto prices
More
